Zafgen Inc. (NASDAQ:ZFGN)’s share price rose 3% on Thursday . The company traded as high as $6.48 and last traded at $6.44, with a volume of 219,670 shares. The stock had previously closed at $6.25.

ZFGN has been the subject of a number of analyst reports. Royal Bank Of Canada reissued an “outperform” rating and set a $19.00 target price on shares of Zafgen in a research note on Tuesday, April 5th. Leerink Swann reissued a “hold” rating and set a $6.00 target price on shares of Zafgen in a research note on Monday, April 11th. FBR & Co reissued a “buy” rating and set a $20.00 target price on shares of Zafgen in a research note on Monday, April 4th. Finally, Zacks Investment Research raised shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research note on Thursday, May 12th. Four equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Zafgen presently has an average rating of “Buy” and an average target price of $11.94.

The company has a 50 day moving average price of $6.45 and a 200-day moving average price of $6.58. The company’s market capitalization is $180.27 million.

Zafgen (NASDAQ:ZFGN) last released its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.09. During the same quarter in the previous year, the firm posted ($0.53) earnings per share. On average, equities analysts predict that Zafgen Inc. will post ($2.81) EPS for the current fiscal year.

A hedge fund recently bought a new stake in Zafgen stock. Oxford Asset Management purchased a new position in Zafgen Inc. (NASDAQ:ZFGN) during the fourth quarter, Holdings Channel reports. The fund purchased 236,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,497,000. Oxford Asset Management owned approximately 0.87% of Zafgen at the end of the most recent quarter.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.